On 6 August 2025, Intas Pharmaceuticals, and its global subsidiaries operating under the Accord brand, announced the successful acquisition of Udenyca®, biosimilar to Amgen’s Neulasta® (pegfilgrastim), from Coherus Biosciences. The addition of Udenyca® expands Intas and Accord’s biosimilar portfolio, which already includes Accord’s other biosimilar pegfilgrastim, Pelgraz®.
The successful acquisition of Udenyca® follows announcement of the agreement for its sale in December 2024 under which Coherus would receive USD$483.4 million upfront, with up to USD$75 million in potential milestone payments based on net sales performance.
In March 2025, Coherus further announced that it will transfer approximately 50 employees to Intas Pharmaceuticals’ specialty unit, Accord BioPharma. The move will reduce Coherus’ workforce by around 30%, leaving it with approximately 155 employees.